Recruiting
Phase 1

LY4174794

Sponsor:

Eli Lilly and Company

Code:

NCT07654972

Conditions

Obesity

Overweight

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

LY4174794

LY4174794

Placebo

Study Details

Brief summary:

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.

Participation in this study will last about 30 to 39 weeks (7 to 10 months).

Conditions

Obesity

Overweight

Study ID

NCT07654972

Start date

Jun 24, 2026

Status verified date

Aug, 2026

Completion date

Apr, 2029

Anticipated

Primary completion date

Apr, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
  • Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
  • Have had a self-reported stable weight for 3 months prior to screening

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
  • Is an individual of childbearing potential (IOCBP)

Study Design

Enrollment

108 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Part A: LY4174794

Participants will receive LY4174794 administered subcutaneously (SC).

experimental: Part B: LY4174794

Participants will receive LY4174794 administered SC.

placebo comparator: Part A & B: Placebo

Participants will receive placebo administered SC.

experimental: Part C: LY4174794

Participants will receive LY4174794 administered intravenously (IV).

Interventions

LY4174794

Administered SC.

LY4174794

Administered IV.

Placebo

Administered SC.

Primary outcome measure

  • Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through end of the Follow-up (Week 25) ]
  • Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through end of the Follow-up (Week 33) ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

ICON Early Phase Services, LLC

Recruiting

San Antonio, Texas, United States, 78232

Contacts

(210) 225-5437

Principal Investigator:

Cassandra Key

More Information

Sponsor

Eli Lilly and Company

Last update posted

Sep 1, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-09-01.